2023 Q1 Form 10-K Financial Statement

#000095017023007871 Filed on March 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.206M $5.175M $20.15M
YoY Change 25.78% 19.74% 28.17%
% of Gross Profit
Research & Development $18.32M $14.86M $51.01M
YoY Change 67.38% 51.92% 31.01%
% of Gross Profit
Depreciation & Amortization $259.0K -$283.0K $1.023M
YoY Change -37.89% -173.13% -32.25%
% of Gross Profit
Operating Expenses $24.52M $20.03M $71.16M
YoY Change 54.45% 42.05% 30.19%
Operating Profit -$24.52M -$71.16M
YoY Change 54.45% 30.19%
Interest Expense $370.0K $1.853M $1.185M
YoY Change 45.67% -1800.0% 645.28%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$22.20M -$18.18M -$68.24M
YoY Change 38.54% 27.93% 24.91%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$22.20M -$18.18M -$68.24M
YoY Change 38.54% 27.93% 24.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.31 -$1.01
Diluted Earnings Per Share -$0.31 -$0.25 -$1.01
COMMON SHARES
Basic Shares Outstanding 70.80M 68.38M 67.37M
Diluted Shares Outstanding 72.33M 67.37M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $257.7M $276.6M $276.6M
YoY Change 6.21% 32.74% 32.74%
Cash & Equivalents $36.13M $40.46M $40.46M
Short-Term Investments $221.5M $236.1M $236.1M
Other Short-Term Assets $777.0K $920.0K $9.161M
YoY Change -26.42% 26.2% 183.71%
Inventory
Prepaid Expenses $6.785M $8.241M
Receivables $0.00
Other Receivables
Total Short-Term Assets $265.2M $285.7M $285.7M
YoY Change 7.82% 34.99% 34.99%
LONG-TERM ASSETS
Property, Plant & Equipment $4.656M $3.431M $13.17M
YoY Change 53.11% 4.51% 119.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.088M $674.0K $674.0K
YoY Change 1704.26% 139.01% 139.01%
Total Long-Term Assets $18.95M $13.85M $13.85M
YoY Change 222.78% 120.51% 120.51%
TOTAL ASSETS
Total Short-Term Assets $265.2M $285.7M $285.7M
Total Long-Term Assets $18.95M $13.85M $13.85M
Total Assets $284.2M $299.6M $299.6M
YoY Change 12.83% 37.46% 37.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.136M $2.479M $2.479M
YoY Change 204.34% 22.24% 22.24%
Accrued Expenses $6.836M $5.953M $8.518M
YoY Change 56.14% 19.42% 37.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.64M $11.00M $11.00M
YoY Change 95.53% 33.91% 33.91%
LONG-TERM LIABILITIES
Long-Term Debt $9.893M $9.834M $9.834M
YoY Change 2.25% 2.2% 2.2%
Other Long-Term Liabilities $8.153M $8.865M $8.865M
YoY Change 181.33% 175.05% 175.05%
Total Long-Term Liabilities $9.893M $9.834M $18.70M
YoY Change 2.25% 2.2% 45.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.64M $11.00M $11.00M
Total Long-Term Liabilities $9.893M $9.834M $18.70M
Total Liabilities $31.69M $29.70M $29.70M
YoY Change 62.09% 41.03% 41.03%
SHAREHOLDERS EQUITY
Retained Earnings -$271.1M -$248.9M
YoY Change 37.82% 37.78%
Common Stock $524.1M $519.7M
YoY Change 21.95% 37.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $252.5M $269.9M $269.9M
YoY Change
Total Liabilities & Shareholders Equity $284.2M $299.6M $299.6M
YoY Change 12.83% 37.46% 37.46%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$22.20M -$18.18M -$68.24M
YoY Change 38.54% 27.93% 24.91%
Depreciation, Depletion And Amortization $259.0K -$283.0K $1.023M
YoY Change -37.89% -173.13% -32.25%
Cash From Operating Activities -$20.86M -$15.88M -$58.85M
YoY Change 56.68% 43.34% 38.67%
INVESTING ACTIVITIES
Capital Expenditures $297.0K $343.0K $1.578M
YoY Change -34.0% -228.95% 399.37%
Acquisitions
YoY Change
Other Investing Activities $16.69M -$8.318M -$89.81M
YoY Change -128.25% -89.88% 219.3%
Cash From Investing Activities $16.39M -$8.661M -$91.39M
YoY Change -127.53% -89.5% 221.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 154.0K 506.0K 127.9M
YoY Change -99.68% -99.49% 13.57%
NET CHANGE
Cash From Operating Activities -20.86M -15.88M -58.85M
Cash From Investing Activities 16.39M -8.661M -91.39M
Cash From Financing Activities 154.0K 506.0K 127.9M
Net Change In Cash -4.327M -24.04M -22.43M
YoY Change -81.95% -515.59% -153.84%
FREE CASH FLOW
Cash From Operating Activities -$20.86M -$15.88M -$58.85M
Capital Expenditures $297.0K $343.0K $1.578M
Free Cash Flow -$21.16M -$16.23M -$60.42M
YoY Change 53.71% 50.03% 41.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001645666
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-38542
CY2022 dei Entity Registrant Name
EntityRegistrantName
Kezar Life Sciences, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3366145
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
4000 Shoreline Court
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2022 dei City Area Code
CityAreaCode
650
CY2022 dei Local Phone Number
LocalPhoneNumber
822-5600
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022 dei Trading Symbol
TradingSymbol
KZR
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
551000000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70803759
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
519620000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
377765000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-923000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-291000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248893000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180654000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
269872000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
196876000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
299568000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
217933000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51009000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38935000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30981000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20153000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15724000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11969000
CY2022 us-gaap Operating Expenses
OperatingExpenses
71162000
CY2021 us-gaap Operating Expenses
OperatingExpenses
54659000
CY2020 us-gaap Operating Expenses
OperatingExpenses
42950000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-71162000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-54659000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-42950000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4108000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
188000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1208000
CY2022 us-gaap Interest Expense
InterestExpense
1185000
CY2021 us-gaap Interest Expense
InterestExpense
159000
CY2020 us-gaap Interest Expense
InterestExpense
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-68239000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54630000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-41742000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68493429
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68493429
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56259747
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56259747
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
68000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
56000
CY2022 dei Auditor Firm
AuditorFirmId
185
CY2022 dei Auditor Name
AuditorName
KPMG LLP
CY2022 dei Auditor Location
AuditorLocation
San Francisco, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40456000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62882000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
236105000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
145473000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8241000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2570000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
920000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
729000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
285722000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
211654000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3431000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3283000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9741000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2714000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
674000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
282000
CY2022Q4 us-gaap Assets
Assets
299568000
CY2021Q4 us-gaap Assets
Assets
217933000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2479000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2028000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5953000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4985000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2565000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1199000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10997000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8212000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8865000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3223000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9834000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9622000
CY2022Q4 us-gaap Liabilities
Liabilities
29696000
CY2021Q4 us-gaap Liabilities
Liabilities
21057000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.95
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.95
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67368935
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67368935
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52759335
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52759335
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44004190
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44004190
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-68239000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54630000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-41742000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-49000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-50000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
82000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-583000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-104000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-632000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-154000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
59000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68871000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54784000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41683000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
78046000
CY2020 kzr Stock And Pre Funded Warrants Issued During Period Net Of Offering Costs Value
StockAndPreFundedWarrantsIssuedDuringPeriodNetOfOfferingCostsValue
99161000
CY2020 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
470000
CY2020 kzr Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early Exercises
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises
41000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4943000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
59000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-41742000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
140978000
CY2021 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2070000
CY2021 kzr Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early Exercises
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises
21000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7596000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-154000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54630000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
196876000
CY2022 kzr Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans
ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1319000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14006000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-632000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-68239000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
269872000
CY2022 us-gaap Profit Loss
ProfitLoss
-68239000
CY2021 us-gaap Profit Loss
ProfitLoss
-54630000
CY2020 us-gaap Profit Loss
ProfitLoss
-41742000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1023000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1510000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1544000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
14006000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
7596000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4943000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1401000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1770000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-317000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
212000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
91000
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2022 kzr Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
5787000
CY2021 kzr Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
-1051000
CY2020 kzr Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
1424000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
392000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1814000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1217000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
313000
CY2022 kzr Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
94000
CY2021 kzr Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
1042000
CY2020 kzr Increase Decrease In Operating Lease Asset And Liabilities
IncreaseDecreaseInOperatingLeaseAssetAndLiabilities
900000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58846000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42437000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36949000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1578000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
316000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
194000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
332203000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
156378000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
225728000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
242389000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
128250000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
169424000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-91392000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28444000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56498000
CY2022 kzr Proceeds From Issuance Of Common Stock Under At The Market Offerings Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockUnderAtTheMarketOfferingsNetOfIssuanceCosts
126542000
CY2021 kzr Proceeds From Issuance Of Common Stock Under At The Market Offerings Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockUnderAtTheMarketOfferingsNetOfIssuanceCosts
100970000
CY2020 kzr Proceeds From Issuance Of Common Stock Under At The Market Offerings Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockUnderAtTheMarketOfferingsNetOfIssuanceCosts
0
CY2022 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
469000
CY2022 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
9531000
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2022 kzr Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offerings Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingsNetOfOfferingCosts
0
CY2021 kzr Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offerings Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingsNetOfOfferingCosts
0
CY2020 kzr Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offerings Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingsNetOfOfferingCosts
99186000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1319000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2084000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
456000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
127861000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112585000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
99642000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-49000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-50000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22426000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41654000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6277000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62882000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21228000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14951000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40456000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62882000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21228000
CY2022 kzr Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
0
CY2021 kzr Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
21000
CY2020 kzr Reclassification Of Employee Stock Liability To Equity Upon Vesting
ReclassificationOfEmployeeStockLiabilityToEquityUponVesting
41000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
47000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
442000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2022 kzr Unpaid Offering Costs In Accrued Liabilities
UnpaidOfferingCostsInAccruedLiabilities
0
CY2021 kzr Unpaid Offering Costs In Accrued Liabilities
UnpaidOfferingCostsInAccruedLiabilities
0
CY2020 kzr Unpaid Offering Costs In Accrued Liabilities
UnpaidOfferingCostsInAccruedLiabilities
25000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
973000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
69000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248900000
CY2022 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
11911699
CY2022 kzr Common Stock Weighted Average Purchase Price Per Share
CommonStockWeightedAveragePurchasePricePerShare
10.95
CY2021 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9352359
CY2021 kzr Common Stock Weighted Average Purchase Price Per Share
CommonStockWeightedAveragePurchasePricePerShare
11.13
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
900000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1493000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and assumptions include the valuation of marketable securities, stock-based compensation, and accrued research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s consolidated financial statements.</span></p>
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
0
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1099000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
1099000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially expose the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. As of December 31, 2022, the majority of the Company’s cash, cash equivalents and marketable securities were held by financial institutions in the United States, while approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was held by a financial institution in Australia. Such deposits in the United States were in excess of insured limits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
807000
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
182408000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
722000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
11849000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
14000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
112520000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
108000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
263664000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
263001000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
11864000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
11849000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
275528000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
274850000
CY2022 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M29D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1167
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1032000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1042000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8033000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6935000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4602000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3652000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3431000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3283000
CY2022 us-gaap Depreciation
Depreciation
1000000.0
CY2021 us-gaap Depreciation
Depreciation
900000
CY2020 us-gaap Depreciation
Depreciation
900000
CY2022Q4 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
1368000
CY2021Q4 kzr Accrued Preclinical And Research Costs Current
AccruedPreclinicalAndResearchCostsCurrent
1043000
CY2022Q4 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
1007000
CY2021Q4 kzr Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
1642000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3260000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1970000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
53000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
231000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
265000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
99000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5953000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4985000
CY2022 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The operating lease agreement has one option to extend the lease term for a period of five years at the fair market rate at the time of the extension.
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
765000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
542000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3767000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3890000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4025000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2418000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14100000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2670000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11430000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2565000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8865000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11430000
CY2022 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1500000
CY2021 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1100000
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1100000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
800000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
800000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
500000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
342000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
431000
CY2022Q4 kzr Cumulative Accretion Of Final Fee
CumulativeAccretionOfFinalFee
176000
CY2021Q4 kzr Cumulative Accretion Of Final Fee
CumulativeAccretionOfFinalFee
53000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9834000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9622000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
5217000
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
4783000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
10000000
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2022Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P20Y
CY2022Q4 kzr Maximum Ownership Percentage Of Holders Upon Exercise Of Warrants
MaximumOwnershipPercentageOfHoldersUponExerciseOfWarrants
0.0499
CY2022Q4 kzr Maximum Ownership Percentage Allowed To Be Increased Or Decreased By Warrant Holders Upon Prior Notice
MaximumOwnershipPercentageAllowedToBeIncreasedOrDecreasedByWarrantHoldersUponPriorNotice
0.1999
CY2022Q4 kzr Class Of Warrants Or Rights Exercised
ClassOfWarrantsOrRightsExercised
0
CY2020Q1 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2020-02-04
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2020Q1 kzr Class Of Warrant Or Rights Expiration Date
ClassOfWarrantOrRightsExpirationDate
2040-02-04
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2884615
CY2020Q2 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2020-06-11
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2020Q2 kzr Class Of Warrant Or Rights Expiration Date
ClassOfWarrantOrRightsExpirationDate
2040-06-11
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
909091
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3793706
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6945184
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.95
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
77363000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3036235
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.80
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
189978
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.44
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1504000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
106631
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.02
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9684810
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.12
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15407000
CY2022Q4 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
5063304
CY2022Q4 kzr Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
6.85
CY2022 kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
P6Y8M12D
CY2022Q4 kzr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue
11532000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1500000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2100000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14006000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7596000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4943000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.006
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.022
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.027
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.025
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-68239000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54630000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-41742000
CY2015Q4 kzr Research And Development Tax Credit Maximum Utilization Against Employers Portion Of Payroll Tax
ResearchAndDevelopmentTaxCreditMaximumUtilizationAgainstEmployersPortionOfPayrollTax
250000
CY2022 kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
79000
CY2021 kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
325000
CY2020 kzr Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses
ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses
373000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.013
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.013
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.011
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.040
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.026
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.242
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.241
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.220
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
3420000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2043000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37939000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
34617000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7603000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
5127000
CY2022Q4 kzr Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
2402000
CY2021Q4 kzr Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
929000
CY2022Q4 kzr Deferredtaxassetsrdcapitalization
Deferredtaxassetsrdcapitalization
7979000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
59343000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42716000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
56983000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41771000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2360000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
945000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
313000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
375000
CY2022Q4 kzr Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
2047000
CY2021Q4 kzr Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
570000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
15200000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12400000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9200000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2500000
CY2022Q4 kzr Liability Related To Uncertain Tax Position
LiabilityRelatedToUncertainTaxPosition
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1643000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
868000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
187000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1066000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
775000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2522000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1643000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-68239000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-54630000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-41742000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67368935
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52759335
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44004190
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.95
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.95
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10119600
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6945184
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4497981

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
kzr-20221231_cal.xml Edgar Link unprocessable
0000950170-23-007871-index-headers.html Edgar Link pending
0000950170-23-007871-index.html Edgar Link pending
0000950170-23-007871.txt Edgar Link pending
0000950170-23-007871-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img141614612_0.jpg Edgar Link pending
img141614612_1.jpg Edgar Link pending
img38338535_0.jpg Edgar Link pending
kzr-20221231.htm Edgar Link pending
kzr-20221231.xsd Edgar Link pending
kzr-ex10_20.htm Edgar Link pending
kzr-ex23_1.htm Edgar Link pending
kzr-ex31_1.htm Edgar Link pending
kzr-ex31_2.htm Edgar Link pending
kzr-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
kzr-20221231_def.xml Edgar Link unprocessable
kzr-20221231_lab.xml Edgar Link unprocessable
kzr-20221231_pre.xml Edgar Link unprocessable
kzr-20221231_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending